Norbert Ndjeka

3 ta ish

National Department of Health, Pretoria, South Africa

1. Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

   S.K. Abidi, Jay Achar, M.M. Assao Neino +34

   MaqolaTuberculosis Research and EpidemiologyEuropean Respiratory Journal20191 iqtibos

   ABIABI:AkademIndex/openalex/2019.article.000020

2. Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026

   Aastha Gupta, Sandeep Juneja, Victor Babawale +12

   MaqolaTuberculosis Research and EpidemiologyPLoS ONE20240 iqtibos

   ABIABI:AkademIndex/openalex/2024.article.000247

3. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

   Anthony J. Garcia‐Prats, Maria Garcia‐Cremades, Vivian Cox +97

   Sharh maqolaTuberculosis Research and EpidemiologyThe Lancet Child & Adolescent Health20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.review-article.000036